Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial

References

• Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL, AGEDD Adult Pneumococcal Burden Study Team. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8(4):e60273. doi:10.1371/journal.pone.0060273.
   PubMed Web of Science ®Google Scholar
• Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398–10. doi:10.1016/j.vaccine.2011.02.088.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. doi:10.1016/S0140-6736(09)61204-6.
   PubMed Web of Science ®Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Luksic I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744–57. doi:10.1016/S2214-109X(18)30247-X.
   PubMed Web of Science ®Google Scholar
• Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]). Full Prescribing Information. Philadelphia, PA: Pfizer Inc; 2017.
   Google Scholar
• Hausdorff WP, Hanage WP. Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358–74. doi:10.1080/21645515.2015.1118593.
   PubMed Web of Science ®Google Scholar
• Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, Ostrosky-Zeichner L, Peyrani P, Wunderink RG, Sherwin R, et al. Pneumococcal epidemiology among US adults hospitalized for community-acquired pneumonia. Vaccine. 2019;37(25):3352–61. doi:10.1016/j.vaccine.2019.04.087.
   PubMed Web of Science ®Google Scholar
• van der Linden M, Falkenhorst G, Perniciaro S, Imohl M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One. 2015;10(7):e0131494. doi:10.1371/journal.pone.0131494.
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. doi:10.1371/journal.pone.0177113.
   PubMed Web of Science ®Google Scholar
• Prevnar 20 (pneumococcal 20-valent conjugate vaccine). Full Prescribing Information. Philadelphia, PA: Pfizer Inc; 2023.
   Google Scholar
• Wroe PC, Lee GM, Finkelstein JA, Pelton SI, Hanage WP, Lipsitch M, Stevenson AE, Rifas-Shiman SL, Kleinman K, Dutta-Linn MM, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J. 2012;31(3):249–54. doi:10.1097/INF.0b013e31824214ac.
   PubMed Web of Science ®Google Scholar
• Flasche S, Van Hoek AJ, Sheasby E, Waight PA, Andrews N, Sheppard CL, George R, Miller E. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 2011;8(4):e1001017. doi:10.1371/journal.pmed.1001017.
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, Krogfelt KA, Konradsen HB, Benfield TL. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6(5):e1000081. doi:10.1371/journal.pmed.1000081.
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D, Microbiologists of Epibac, ORP Networks. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill. 2008;13(35):18962. doi:10.2807/ese.13.35.18962-en.
   PubMedGoogle Scholar
• Senders S, Klein NP, Lamberth E, Thompson A, Drozd J, Trammel J, Peng Y, Giardina PC, Jansen KU, Gruber WC, et al. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States. Pediatr Infect Dis J. 2021;40(10):944–51. doi:10.1097/INF.0000000000003277.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Data from Pfizer’s adult and pediatric clinical trial programs for 20-valent pneumococcal conjugate vaccine presented at IDWeek 2020. [accessed 2022 Mar 22]. https://www.pfizer.com/news/press-release/press-release-detail/data-pfizers-adult-and-pediatric-clinical-trial-programs-20.
   Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. Vaccine. 2010;28(34):5513–23. doi:10.1016/j.vaccine.2010.06.026.
   PubMed Web of Science ®Google Scholar
• Tan CY, Immermann FW, Sebastian S, Pride MW, Pavliakova D, Belanger KA, Watson W, Scott DA, Sidhu M, Jansen KU, et al. Evaluation of a validated Luminex-based multiplex immunoassay for measuring immunoglobulin G antibodies in serum to pneumococcal capsular polysaccharides. mSphere. 2018;3(4):e00127–00118. doi:10.1128/mSphere.00127-18.
   PubMed Web of Science ®Google Scholar
• The Annie E. Casey Foundation. KIDS COUNT data center. Child population by race and age group in the United States. [accessed 2021 June 29]. https://datacenter.kidscount.org/data/tables/8446-child-population-by-race-and-age-group#detailed/1/any/false/1729,37,871,870,573,869,36,868,867,133/68,69,67,12,70,66,71,13|62,63,30/17077,17078.
   Google Scholar
• Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger. [accessed 2021 Dec 21]. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf.
   Google Scholar
• Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2). doi:10.1128/CMR.00084-18.
   PubMed Web of Science ®Google Scholar
• Pobre K, Tashani M, Ridda I, Rashid H, Wong M, Booy R. Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines. Vaccine. 2014;32(13):1423–30. doi:10.1016/j.vaccine.2014.01.047.
   PubMed Web of Science ®Google Scholar
• Ventola CL. Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations. Pharmacy And Therapeutics. 2016;41(7):426–36. https://www.ncbi.nlm.nih.gov/pubmed/27408519.
   Google Scholar